Following its big-pharma peers, Janssen Pharmaceutical Cos. announced Jan. 22 the formation of a Global Public Health Group (GPH), aligning the company’s science and global market access models under a single entity. The idea is to put more focus on how it develops and delivers its portfolio of infectious disease products to the many geographic markets it serves, particularly the resource-limited countries of Africa and Asia.
The group, which was given the same management structure and standing as other therapeutic areas at Janssen, partners with other business units as needed to advance its public health goals....